KYMR Kymera Therapeutics, Inc. stock chart & analysis
Conviction 11LongHealthcareScan · Fri, Nov 6, 2026Kymera Therapeutics, Inc. (KYMR) closed at $131.73 (+2.82%) on Nov 6, 2026. Its chart shows a symmetrical triangle pattern. Price is above its 50-day and above its 200-day moving average. RSI(14) 65, RS Rating 97, -4.6% from its 52-week high, +69.3% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Trade plan
This setup's entry, stop and target are in Pro.
Free accounts get the full plan on the top 3 setups of every lane.
Financials as of Wed, Sep 30, 2026 · quarterly.
KYMR technical analysis
Trend
KYMR is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 13.9% above the 50-day ($115.67) and 34.5% above the 200-day ($97.91). ADX(14) at 29 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 65, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 97 puts its weighted 12-month performance ahead of about 97% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 1.0× its 20-day average. It trades about $116.4M a day on average. ATR(14) is $6.80, 5.2% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.10) shows accumulation.
Key levels
The chart pattern's support is $109.35 and its resistance $111.40. The 52-week range is $56.75 to $138.00; price is 4.6% below the high and 132.1% above the low. The VWAP anchored at the 52-week high is $130.22, below price.
Performance
KYMR returned +4.0% (1 week), +20.5% (1 month), +21.3% (3 months), +53.0% (6 months), +119.9% (1 year), +69.3% (year to date).
About Kymera Therapeutics, Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Biological Products, (No Diagnostic Substances) · Listed 2020 · 253 employees
Insider activity
SEC Form 4 transactions in KYMR · open-market 5 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Rooney Terence Chief Medical Officer · Stock Option (Right to Buy) · 2026-07-27 | Grant | 76K | — | 2026-07-27 | 2026-07-27 |
Rooney Terence Chief Medical Officer · Common Stock · 2026-07-27 | Grant | 38K | — | 2026-07-27 | 2026-07-27 |
Mainolfi Nello Chief Executive Officer · Common Stock · 2026-07-07 | Exercise | 50K | $104K | 2026-07-07 | 2026-07-07 |
Mainolfi Nello Chief Executive Officer · Common Stock · 2026-07-07 | Sell | 50K | $6.0M | 2026-07-07 | 2026-07-07 |
Mainolfi Nello Chief Executive Officer · Stock Option (Right to Buy) · 2026-07-07 | Exercise | 45.56K | — | 2026-07-07 | 2026-07-07 |
Mainolfi Nello Chief Executive Officer · Stock Option (Right to Buy) · 2026-07-07 | Exercise | 4.44K | — | 2026-07-07 | 2026-07-07 |
Booth Bruce Director · Common Stock · 2026-06-29 | Sell | 157 | $17K | 2026-06-29 | 2026-06-30 |
Booth Bruce Director · Common Stock · 2026-06-29 | Sell | 7.83K | $860K | 2026-06-29 | 2026-06-30 |
Booth Bruce Director · Common Stock · 2026-06-29 | Sell | 7.6K | $841K | 2026-06-29 | 2026-06-30 |
Booth Bruce Director · Common Stock · 2026-06-29 | Sell | 907 | $101K | 2026-06-29 | 2026-06-30 |
SEC filings
EDGAR filings in KYMR · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.